NVO is cutting 9,000 jobs, targeting DKK 8 billion in savings, and shifting focus to obesity and diabetes R&D to regain growth momentum.

The Danish drugmaker plans to cut 9,000 jobs or 11% of its workforce, which would save it 8 billion Danish krone ($1.25 billion) annually.

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that David Moore, Executive Vice President, US Operations at Novo Nordisk A/S and President at ...

Endocrinologists say the early momentum for Mounjaro was expected, given its dual indication for diabetes and obesity ...

The Danish government has joined forces with Novo Holdings, the investment arm of Novo Nordisk’s controlling foundation, to anchor a €300 million, which is ...

Many drug trials are vetted by companies with ties to the drugmakers, raising concerns about conflicts of interest and patient safety.

The Issaquah-based wholesale retailer is collaborating with Novo Nordisk, the Danish pharmaceutical company that manufactures Wegovy and Ozempic.

Novo Nordisk, the maker of Ozempic and Wegovy, announced Friday that Costco pharmacies will sell a four-week supply of the injectable pens for $499 out of pocket.

The announcement comes as GLP-1 weight loss medications gain popularity and more Americans turn to copycat versions due to high prices.

Hims & Hers' recent partnership with Marius Pharmaceuticals for Kyzatrex positions it to capture a larger share. See why I rate HIMS stock a Buy.

India’s anti-obesity pharmaceutical market is valued at ₹859 crore, having recorded a five-fold increase over five years with a 46% CAGR ...

Skye Bioscience (Nasdaq: SKYE) reported topline data from a mid-stage trial showing that its obesity drug nimacimab failed to cut weight on its own but added meaningful benefit when paired with Novo ...